Dimitri Bennett, MD, MPH

Dimitri Bennett, MD, MPH
CPHI Adjunct Fellow

Title: Director Pharmacoepidemiology, Takeda Pharmaceutical
Email: dimitri.bennett@takeda.com 

Public Health Interests:

Research in diabetes, HIV/AIDS, health policy, infectious diseases, chronic diseases and oncology/hematology

Current Public-Health Related Activities:

I am a physician with 18 years of international comprehensive experience in the healthcare industry (Biopharmaceuticals and Public Health). Specifically, I have experience to generate real world evidence by conducting high-quality clinical trials and pharmacoepidemiologic studies worldwide in international and emerging markets to inform public health, drug development strategies, optimize clinical development, pharmacovigilance and regulatory submission programs across different Franchises, internal stakeholders including Global Clinical Safety and Pharmacovigilance (GCSP), Medical Affairs, Clinical Development, Regulatory, Health Outcomes, Marketing/Payers, and Legal stakeholders.

I began my independent career as a physician-scientist at the New Jersey State Department of Health. I moved back to Pennsylvania, Philadelphia in 2002 to work as the Associate Director of Epidemiology, Worldwide Epidemiology Group for GlaxoSmithKline and then Director Epidemiology at GSK. My primary responsibility included the leadership for the strategic and business development of global epidemiology programs and evidence generation for Oncology and Haematology/Supportive Care products, Cardiovascular and Infectious Diseases compound across the pipeline, from early development through to marketed products. Additional activities included presentation of epidemiological studies at various congresses and meetings.

I am currently the Director of Pharmacoepidemiology for Takeda Pharmaceutical where my primary responsibility include the leadership for development, data management, data interpretation, and dissemination of Real World Evidence from observational studies including PASS, DUS to fulfill post-marketing commitments using ENCePP methodological guidelines for CVD/Metabolic TA. Additional responsibilities include input into benefit-risk assessment for CVD and metabolic diseases, development of benefit-risk plans for clinical and post approval studies, support safety signal medical evaluation, interpretation and management for the Takeda CVD and Metabolic clinical development and post marketing portfolio.

Select Publications:

Bennett, D, Abate J, Abrahamson PE. Characteristics of Patients with Venous Thromboembolism and Atrial Fibrillation in Venezuela. BMC Public Health 2011; 11:415

Walker MA and Bennett, D. Epidemiology and Outcomes in Patients with Atrial Fibrillation in the United States. Heart Rhythm 2008; 5(10):1365-1372

Bennett, D, M. Elizabeth Hodgson, Amit Shukla, John W. Logie. Prevalence of Diagnosed Adult Immune Thrombocytopenia in the United Kingdom. Adv Ther. 2011;Dec 28(12):1096-1104

Enger C, Bennett, D, Forssen U, Fogarty P, and McAfee AT. Comorbidities in patients with persistent or chronic immune thrombocytopenia (ITP). Int J Hematol 2010;92:289-295